CTLA4 and neoplasm: Dewan et al. reported that 3 × 8 Gy and 5 × 6 Gy, in contrast to a single dose of 20 Gy RT, in combination with anti-CTLA-4 mAb (monoclonal antibody), resulted in enhanced tumor growth inhibition in breast (TSA) and colon (MCA38) carcinoma models, at both primary and secondary tumors, with induction of an abscopal effect [25].